Next 10 |
home / stock / epgny / epgny news
Summary Guardant Health derives most of its revenue from FDA-approved liquid-biopsy services as opposed to CLIA-waived laboratory-developed tests "LDT". As the FDA prepares to extend its regulatory arm over LDT, it might be a good idea to shift your investment exposure to companie...
Summary As EXAS continues shifting its business models from "growth at all costs" to "profitable growth" in response to rising capital costs, its sales will expand at a slower pace. Despite the expected normalization in growth, in my view, the market will likely reward improved ma...
Under the primary base case analysis, annual m SEPT9 screening resulted in more Quality-adjusted-life-years gained (QALYG), CRC cases averted and CRC deaths averted than both annual FIT screening and Cologuard ® every three years, albeit at a higher colonoscopy referral rate ...
Dover, Delaware--(Newsfile Corp. - June 17, 2020) - Encode Ideas, L.P. Initiates Research on Epigenomics AG (Xetra: ECX.DE) (FSE: ECX) (OTC: EPGNF). The full research publication is available here and available on our website at www.encodelp.com . A summary follows: Encode Ideas, L.P., a h...
- Adherence rates and screening intervals recognized as decisive elements of successful screening strategies - BERLIN, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), today reported on micro-simulation model results indicating th...
- Adherence rates and screening intervals recognized as decisive elements of successful screening strategies - BERLIN, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), today reported on micro-simulation model results indicating th...
BERLIN, July 24, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology, today reported new study results suggesting...
- Company recognized for its leadership in advancing blood-based tests to diagnose cancer - BERLIN and SAN DIEGO, July 11, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) announced today that it was selected by MedTech Outlook to receive the 20...
- Minimally-invasive blood test could complement colonoscopy in high-risk LS patients who are non-compliant with colonoscopy screening recommendations or may develop precancerous lesions in the interval between colonoscopies - BERLIN, June 17, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (F...
– Data Presented at DDW 2019 Show 93.6% Acceptance Rate Among Patients Unwilling or Unable to Complete Other CRC Screening Tests – BERLIN and SAN DIEGO, May 19, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a mole...
News, Short Squeeze, Breakout and More Instantly...
Epigenomics Ag S/Adr Company Name:
EPGNY Stock Symbol:
OTCMKTS Market:
Under the primary base case analysis, annual m SEPT9 screening resulted in more Quality-adjusted-life-years gained (QALYG), CRC cases averted and CRC deaths averted than both annual FIT screening and Cologuard ® every three years, albeit at a higher colonoscopy referral rate ...
Dover, Delaware--(Newsfile Corp. - June 17, 2020) - Encode Ideas, L.P. Initiates Research on Epigenomics AG (Xetra: ECX.DE) (FSE: ECX) (OTC: EPGNF). The full research publication is available here and available on our website at www.encodelp.com . A summary follows: Encode Ideas, L.P., a h...
- Adherence rates and screening intervals recognized as decisive elements of successful screening strategies - BERLIN, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), today reported on micro-simulation model results indicating th...